Antibodies for CD47 (Hu5F9-G4) and SIRP1α (CC-95251 and 1H9), as well as SIRP1αFc fusion protein (TTI-621), promote phagocytosis, reducing tumor burden in numerous animal models, and are being tested in a clinical trial [125,126,127]. This evidence concerns the gene CD47 and neoplasm.